Deposition and effects of inhaled corticosteroids

Clinical Pharmacokinetics

Volumn 42, Issue 6, 2003, Pages 529-544

  Newman, Stephen P ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; TRIAMCINOLONE;

DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DYSPHONIA; FORCED EXPIRATORY VOLUME; HUMAN; METERED DOSE INHALER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTISCANNING; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THRUSH;

EID: 0038383772     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342060-00003     Document Type: Review

References (110)

1. Dolovich MB. Physical principles underlying aerosol therapy. J Aerosol Med 1989; 2: 171-85
2. British Asthma Guildelines Coordinating Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1-S24
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157: S1-S53
4. Howarth PH. What is the nature of asthma and where are the therapeutic targets? Respir Med 1997; 91 Suppl. A: 2-8
5. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 Suppl. A: 22-8
6. Thorsson L, Edsbäcker S, Källén A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 529-38
7. Bousquet J, D'Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16: 808-16
8. Derendorf H, Daley-Yates P, Pierre LN, et al. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J 2001; 17: 157-8
9. Newman SP. Devices for inhaling medications. In: Clark TJH, Lee T, Godfrey S, Thomson NC, editors. Asthma. 4th ed. London: Edward Arnold Limited, 2000: 329-54
10. Partridge MR, Woodcock AA, Sheffer AL, et al. Chlorofluorocarbon-free inhalers: are we ready for the change? Eur Respir J 1998; 11: 1006-8
11. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996; 9: 55-70
12. Lipworth BJ. Targets for inhaled treatment. Respir Med 2000; 94 Suppl. D: S13-6
13. Poulter LW. Central inflammation is more important than peripheral inflammation. Respir Med 1997: 91 Suppl. A: 9-10
14. Hamid QA. Peripheral inflammation is more important than central inflammation. Respir Med 1997; 91 Suppl. A: 11-2
15. Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 2001; 51: 289-99
16. Ganderton D, Byron P. Harmonising inhaler testing across the Pharmacopeias. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press, 1996: 283-92
17. Hindle M, Byron P. Impaction and impingement techniques for powder inhalers: comparisons, problems and validation. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press, 1996: 263-72
18. Wright P. Next generation impactor: European update. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove (IL): Interpharm Press, 1998: 479-81
19. Hallworth GW. Particle size analysis of therapeutic aerosols. In: Morén F, Dolovich MB, Newhouse MT, et al., editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier, 1993: 351-74
20. Kenyon CJ, Dewsbury NJ, Newman SP. Differences in aerodynamic particle size distribution of innovator and generic beclomethasone dipropionate aerosols used with and without a large volume spacer. Thorax 1995; 50: 846-50
21. Newman SP, Talaee N, Clarke SW. Salbutamol aerosol delivery with the Rondo spacer. Acta Ther 1991; 17: 49-58
22. Zanen P, Lammers JWJ. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol 1995; 48: 179-84
23. Kamada AK, Szefler SJ. How should inhaled glucocorticoids be compared? J Allergy Clin Immunol 1997; 99: 735-7
24. Pauwels R, Newman SP, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered dose inhalers. Eur Respir J 1997; 10: 2127-38
25. Barnes PJ. Corticosteroids: mode of action and place in management. In: Clark TJH, Lee T, Godfrey S, et al., editors. Asthma. 4th ed. London: Edward Arnold Limited, 2000: 304-28
26. Engel T, Heinig JH, Malling H-J, et al. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy 1989; 44: 220-5
27. O'Callaghan C, Lynch J, Cant M, et al. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation and avoiding multiple actuations of drug. Thorax 1993; 48: 603-6
28. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-3
29. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476-82
30. Derendorf H, Hochhaus G, Möllman H. Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med 2001; 14 Suppl. 1: S9-S17
31. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001; 6: 367-75
32. Lipworth BJ. The comparative safety/efficacy of HFA-BDP. Respir Med 2000; 94 Suppl. D: S21-6
33. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50: 105-10
34. Davies DS. Pharmacokinetics of inhaled substances. Postgrad Med J 1975; 51 Suppl. 7: 69-75
35. Auty RM, Brown K, Neale MG, et al. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br J Dis Chest 1987; 81: 371-80
36. Falcoz C, Oliver R, McDowell JE, et al. Bioavailability of orally administered micronized fluticasone propionate. Clin Pharmacokinet 2000; 39 Suppl. 1: 9-15
37. Borgström L, Derom E, Stahl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-40
38. Borgström L, Newman S, Weisz A, et al. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion method. J Pharm Sci 1992; 81: 753-5
39. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J 1994; 7: 1839-44
40. Thorsson L, Edsbäcker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998; 12: 1340-5
41. Olsson B, Borgström L, Asking L, et al. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press, 1996: 273-81
42. Newnham DM, McDevitt DG, Lipworth BJ. Comparison of the extrapulmonary beta-2 adrenoceptor responses and pharmacokinetics of salbutamol metered dose-inhaler and modified actuator device. Br J Clin Pharmacol 1993; 36: 445-50
43. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34: 311-5
44. Lipworth BJ, Jackson CM. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol 1999; 48: 866-8
45. Chrystyn H, Corlett SA, Silkstone V. Lung bioavailability of generic and innovator salbutamol MDIs [letter]. Thorax 1996; 51: 658
46. Lipworth BJ, Clark DJ. Lung bioavailability of generic and innovator salbutamol MDIs [letter]. Thorax 1996; 51: 658
47. Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996; 41: 247-9
48. Chrystyn H, Allen MB, Corlett SA, et al. Simultaneous measurement of pharmacodynamic and pharmacokinetic parameters which can be used to evaluate the influence of inhaled salbutamol [abstract]. Am J Respir Crit Care Med 1998; 157: A636
49. Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Respir Med 1999; 93: 123-33
50. Dolovich MB. Measuring total and regional lung deposition using inhaled radiotracers. J Aerosol Med 2001; 14 Suppl. 1: S35-44
51. Fleming JS, Conway JH. Three-dimensional imaging of aerosol deposition. J Aerosol Med 2001; 14: 147-53
52. Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des 2000; 6: 1631-51
53. Newman SP. Scintigraphic assessment of pulmonary delivery systems. Pharm Tech 1998 Jun; 22: 78-94
54. Chan H-K. Use of single photon emission computed tomography in aerosol studies. J Aerosol Med 1993; 6: 23-36
55. Rhodes CG, Hughes JMB. Pulmonary studies using positron emission tomography. Eur Respir J 1995; 8: 1001-17
56. Phipps PR, Gonda I, Bailey DL, et al. Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis 1989; 139: 1516-23
57. Dolovich M, Hahmias C, Coates G. Unleashing the PET: 3D imaging of the lung. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VII. Raleigh (NC): Serentec Press, 2000: 215-30
58. 18FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 11: 1342-8
59. 11C triamcinolone acetonide. J Nucl Med 2000; 41: 1603-11
60. Conway JH, Holgate ST. Targeting therapy to inflamed airways in asthma. J Aerosol Med 1994; 7: 161-5
61. Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medications. Chest 1998; 113: 957-63
62. Borgström L, Bondesson E, Morén F, et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7: 69-73
63. Kenyon CJ, Thorsson L, Borgström L, et al. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J 1998; 11: 606-10
64. Thorsson L, Kenyon CJ, Newman SP, et al. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm 1998; 168: 119-27
65. Pitcairn GR, Lankinen T, Seppälä O-P, et al. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J Aerosol Med 2000; 13: 97-104
66. Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000; 16: 178-83
67. Richards JC, Hirst PH, Pitcairn GR, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14: 197-208
68. Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med 2001; 95: 720-7
69. Newman SP, Pitcairn GR, Adkin DA, et al. Comparison of beclomethasone dipropionate delivery by Easyhaler dry powder inhaler and pMDI plus large volume spacer. J Aerosol Med 2001; 14: 217-25
70. Warren SJ, Taylor G. Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (Clickhaler), a conventional metered dose inhaler and MDI plus spacer. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove (IL): Interpharm Press, 1998: 453-55
71. Conway JH, Walker P, Fleming JS, et al. Three-dimensional description of the deposition of inhaled terbutaline sulphate administered via Turbuhaler. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VII. Raleigh (NC): Serentec Press, 2000: 607-9
72. Newman SP, Steed K, Hooper G, et al. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurised metered dose inhaler. Pharm Res 1995; 12: 231-6
73. Snell NJC. Equivalence testing: the special case of inhaled medications. Int J Pharm Med 1998; 12: 245-6
74. Newman SP. How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med 1998; 11 Suppl. 1: S97-S104
75. Farr SJ, Warren SJ, Lloyd P, et al. Comparison of in vitro and in vivo efficiencies of a novel unit-dose aerosol generator and a pressurized metered dose inhaler. Int J Pharm 2000; 198: 63-70
76. Borgström L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J Allergy Clin Immunol 1999; 104: S246-9
77. Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000; 208: 49-60
78. Fowler SJ, Lipworth BJ. Therapeutic equivalence of inhaled salbutamol. Thorax 2000; 55: 347-8
79. Dolovich MB, Ruffin R, Corr D, et al. Clinical evaluation of a new demand-inhalation MDI aerosol delivery device. Chest 1983; 84: 36-41
80. Melchor R, Biddiscombe MF, Mak VHF, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airways obstruction. Thorax 1993; 48: 506-11
81. Falcoz C, Mackie AE, Horton J, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in asthmatic patients [abstract]. Br J Clin Pharmacol 1997; 43: 541P-2P
82. Mackie AE, Falcoz C, McDowall JE, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in healthy subjects [abstract]. Br J Clin Pharmacol 1997; 43: 540P-1P
83. Daley-Yates PT, Tournant J, Kunka R. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet 2000; 39 Suppl. 1: 39-45
84. Lipworth BJ, Clark DJ. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 1997; 52: 1036-9
85. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clin Immunother 1996; 6: 273-99
86. Mackie AE, McDowell JE, Ventresca P, et al. Systemic exposure to fluticasone propionate administered via metered dose inhaler containing chlorofluorocarbon or hydrofluorocarbon propellant. Clin Pharmacokinet 2000; 39 Suppl. 1: 17-22
87. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001; 14 Suppl. 1: S19-26
88. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996; 42: 697-705
89. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-53
90. Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998; 92 Suppl. A: 9-15
91. 1 as HFA-BDP [abstract]. Am J Respir Crit Care Med 1998; 157: A405
92. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215-22
93. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92 Suppl. A: 23-31
94. Muir J-J. An overview of the clinical efficacy of HFA-BDP in asthma. Respir Med 2000; 94 Suppl. D: S17-20
95. Reichel W, Dahl R, Ringdal N, et al. Extrafine beclomethasone dipropionate breath-actuated inhaler (400μg/day) versus budesonide dry powder inhaler (800μg/day) in asthma. Int J Clin Pract 2001; 55: 100-6
96. Milanowski J, Qualtrough J, Perrin VL. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA-134a) is equivalent to BDP-CFC for the treatment of asthma. Respir Med 1999; 93: 245-51
97. Lipworth BJ, Jackson CM. Letter to editor. Respir Med 2000; 94: 177
98. Chrystyn H. Letter to editor. Respir Med 2000; 94: 177-9
99. Zanen P. Letter to editor. Respir Med 2000; 94: 180-1
100. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87: 405-11
101. O'Callaghan C, Barry P. Delivering inhaled corticosteroids to patients. BMJ 1999; 318: 410-1
102. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997; 52: 55-8
103. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. Thorax 1993; 48: 233-8
104. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148: S1-S26
105. Hämäläinen KM, Granander M, Toivanen P, et al. Assessment of the systemic effects of budesonide inhaled from Easyhaler and from Turbuhaler in healthy male volunteers. Respir Med 2001; 95: 863-9
106. Thorsson L. Influence of inhaler systems on systemic availability, with focus on inhaled corticosteroids. J Aerosol Med 1995; 8 Suppl. 3: S29-37
107. Thompson PJ, Davies RJ, Young WF, et al. Safety of hydroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 1998; 92 Suppl. A: 33-9
108. Selroos O. Bronchial asthma, chronic bronchitis and pulmonary parenchymal diseases. In: Morén F, Dolovich MB, Newhouse MT, Newman SP, editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier, 1993: 261-89
109. Toogood JH, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment in asthma. Am Rev Respir Dis 1984; 129: 723-9
110. Selroos O, Halme M. Effect of a volumetric spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991; 46: 891-4